Related Experiment Video
Updated: May 28, 2026
05:44
Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
Formulation optimization of solid dispersion of mosapride hydrochloride
Hye Jin Kim1, Su Hyun Lee, Eun Ah Lim
1College of Pharmacy, Sookmyung Women's University, Seoul 140-742, Korea.
Archives of Pharmacal Research
|October 7, 2011
Summary
Mosapride citrate solid dispersions were developed using polymers like Eudragit RSPO and HPMC for controlled release. These formulations effectively extended drug release up to 24 hours, showing potential for treating gastrointestinal disorders.
Area of Science:
- Pharmaceutical Sciences
- Materials Science
Background:
- Mosapride citrate (MSP) is a 5-HT(4) agonist used for gastrointestinal motility disorders.
- Effective drug delivery systems are crucial for optimizing MSP's therapeutic efficacy.
Purpose of the Study:
- To investigate solid dispersion formulations of mosapride citrate (MSP) for controlled release.
- To elucidate the release mechanism and characterize drug-polymer interactions.
Main Methods:
- Solid dispersions prepared via solvent evaporation with various polymers (Eudragit RSPO, HPMC, Kollidon SR) and polyvinylpyrrolidone (PVP).
- Characterization using DSC, XRD, and FT-IR to assess drug state and interactions.
- In vitro dissolution studies to evaluate drug release profiles.
Main Results:
- MSP converted from crystalline to amorphous state within polymeric carriers.
- Eudragit RSPO and HPMC extended drug release up to 24 hours.
- Higher polymer content correlated with improved slow-release characteristics.
Conclusions:
- Solid dispersions of MSP with PVP/Eudragit RSPO or HPMC offer a promising controlled-release system.
- These formulations can enhance therapeutic outcomes for conditions like acid reflux and IBS.
- The amorphous state of MSP in solid dispersions facilitates sustained drug delivery.
Related Concept Videos
01:16Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...